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FIGURE 1 Cardiac Amyloid in Aortic Stenosis
An 88-year-old woman with severe aortic stenosis. (A) DPD scintigraphy fused single-photon emission tomography/computed tomography
illustrating cardiac tracer retention suggestive of cardiac amyloid, with large bilateral pleural effusions. (B) Fluoroscopy demonstrating the
26-mm Edwards Sapien 3 valve (Edwards Lifesciences, Irvine, California) in situ during the transcatheter aortic valve replacement. Note the
pre-existing dual-chamber pacemaker leads.
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464outcomes (procedural approaches, benefits, mortal-
ity). The importance of ongoing studies is high.Paul R. Scully, MBBS
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Therapy for End-Stage
Hypertrophic CardiomyopathyThe Need for Disease-Specific CriteriaCardiac resynchronization therapy (CRT) is a well-
established treatment for patients with heart failure
(HF) with reduced left ventricular ejection fraction
(LVEF), whereas its role in patients with preserved
LVEF is controversial at best (1). Hypertrophic car-
diomyopathy (HCM) is characterized by normal or
enhanced LVEF, even in patients with severe
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465congestive symptoms. About 5% to 7% of patients
with HCM, however, develop systolic dysfunction
with LVEF values <50% and as low as 25% to 30%,
subtended by extensive myocardial fibrosis (“end-
stage”) (2). In this subset, CRT appears a reasonable
option, but the limited data available show conflicting
results (1,3), possibly because eligibility criteria are
undefined and variably extrapolated from systolic
HF. Whether dilated cardiomyopathy (DCM) criteria
apply to HCM is unresolved. Therefore, we aimed to
evaluate the effects CRT on symptomatic status and
outcome in end-stage HCM in a tertiary referral
center.
We evaluated patients with HCM consecutively
seen from 2000 to 2016; patients with storage or
metabolic disease were excluded. We identified 61
patients with end-stage HCM, of whom 13 (21%)
received CRT (7 females, age at diagnosis 29  10
years). Patients with CRT were <1% of the total
cohort.
At CRT implantation (age 49  12 years), 8 pa-
tients were in New York Heart Association (NYHA)
functional class II and 5 patients in class III/IV.
Cardiopulmonary exercise testing was performed in
8 patients, showing marked VO2 reduction (average
52% of predicted). Left bundle branch block (LBBB)
was present in 12 of 13 patients with average QRS
duration of 173  27 ms, and LVEF was 42  12%
(2 patients were implanted despite EF >50% due to
refractory HF and marked intraventricular dyssyn-
chrony). Nine patients had paroxysmal atrial fibril-
lation, evolving into permanent in 6; 4 required
ablate-and-pace. The CRT group showed a higher
proportion of LBBB compared with end-stage pa-
tients without CRT (12 of 13 vs. 9 of 48; p < 0.01); no
difference was seen in NYHA functional class, age,
LVEF, and diuretics dose.
At 1 year, 7 patients (54%) improved $1 NYHA
functional class, 3 reported no change, and 2
worsened $1 class. No differences were observed in
LVEF and left ventricular (LV) volumes. At end of
follow-up (5.2  3.1 years after implantation), 6 pa-
tients died (46%) due to HF (n ¼ 3), cerebral hemor-
rhage, cardiorenal complications, and heart
transplant complications. Two patients were alive
after heart transplantation. In the 7 CRT responders,
symptomatic improvement lasted 2.7  2.5 years. At
final evaluation, however, there was no sustained
symptomatic improvement compared with baseline.
No difference in survival was evident between CRT
and no-CRT end-stage patients during comparable
follow-up (p ¼ 0.46). Time from onset of NYHA
functional class III/IV symptoms to listing intransplant candidates was also similar (2.1 vs. 1.9
years, respectively; p ¼ 0.73). Two long-term CRT
responders (sustained improvement to NYHA func-
tional class II) were observed: a 48-year-old woman
with LVEF of 32% and LBBB, and a 32-year-old
woman with normal systolic function (LVEF 64%) and
marked mitral regurgitation associated with LBBB
following extensive surgical myectomy.
Patients vaguely fulfilling DCM criteria for CRT
implantation are rare in large HCM cohorts and bear
an ominous prognosis with an overall mortality or
need for transplantation exceeding 50% at 5 years.
CRT provided no significant advantage over phar-
macological therapy alone, and failed to induce LV
reverse remodeling or improvement in systolic func-
tion. We did observe transient symptomatic
improvement at 1 year, but this effect was not main-
tained long term. A likely explanation for lack of CRT
efficacy lies in the peculiar pathophysiology of HCM.
Imaging and pathology studies (4,5) show that more
than one-third of the LV in end-stage patients is
replaced by fibrosis, which predominates, but is not
confined to, the anteroseptal region and is often
diffuse. Such substrate appears hardly amenable to
the beneficial effects of CRT. Therefore, DCM criteria
combining systolic dysfunction and LBBB are not
applicable to HCM patients. The fact that individual
responders exist, however, suggests that disease-
specific eligibility criteria should be sought, rather
than admitting defeat too early over this important
therapeutic issue. A case-by-case evaluation of HF
symptoms, QRS duration, LV dyssynchrony, and
mechanism of mitral regurgitation may help identify
patients who will benefit from CRT. Need for perma-
nent pacing should prompt consideration for CRT in
order to prevent worsening of diastolic function.
Most importantly, exploring earlier stages of HCM
progression and assessing the burden of fibrosis by
cardiac magnetic resonance may be key in patient
selection (5). Unfortunately, too few of our patients
had cardiac magnetic resonance before CRT (n ¼ 5) to
address this important issue.*Francesco Cappelli, MD
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and Functionality in
Familial HypercholesterolemiaCurrent research is focused on improving high-
density lipoprotein (HDL) function rather than
simply targeting an increase in high-density
lipoprotein-cholesterol (HDL-C) levels (1). The results
of several recent studies indicate that stimulation
of the HDL-dependent cholesterol efflux from
macrophage foam cells mediated by the adenosine–
triphosphate-binding cassette (ABC) A1 transporter,
considered to be the major atheroprotective property
of HDL, is inversely associated with the incidence
of cardiovascular disease events (1). Familial hyper-
cholesterolemia (FH) is an inherited autosomal
dominant disorder mainly caused by mutations in the
low-density lipoprotein receptor (LDLR) gene and
characterized by high low-density lipoprotein-
cholesterol (LDL-C) levels, which often are associated
with low HDL-C levels (2). Several studies have re-
ported that patients with FH display qualitative
abnormalities in the HDL particles that may be critical
for HDL remodeling and macrophage cholesterol
efflux (2). Furthermore, recent evidence indicates
that hypercholesterolemia alters HDL lipidome andprotein cargo in pigs, thereby impairing its ability
to promote macrophage cholesterol efflux (3). The
potential of HDL particles to be remodeled in
nontreated patients with FH and the effect of
such remodeling on the HDL-mediated macrophage
cholesterol efflux have not been investigated.
In the present study, we evaluated the HDL-
associated master remodeling lipid transfer proteins
and enzymes, and their potential to alter HDL
composition and macrophage cholesterol efflux in
nontreated patients with FH with an identified LDLR
mutation and in normolipidemic subjects of similar
age (51.0  1.21 years of age and 49.8  1.98 years of
age in adult subjects, respectively; 15.9  0.64 years
of age and 16.1  0.75 years of age in adolescent
subjects, respectively) and sex distributions (Table 1).
All studied subjects were recruited from the Vascular
Medicine and Metabolism Unit of the Sant Joan Uni-
versity Hospital and the Department of Biochemistry
of the Hospital de la Santa Creu i Sant Pau. The study
was performed in accordance with the ethical
principles set forth in the Declaration of Helsinki.
As expected (2), adult patients with FH showed
higher levels of LDL-C and apolipoprotein (apo) B,
whereas HDL-C and apoA-I levels were lower than
those of control subjects. Importantly, nontreated
patients with FH were also characterized by higher
cholesteryl ester transfer protein (CETP) (4,5) and
phospholipid transfer protein (PLTP) activities but
reduced lecithin-cholesterol acyltransferase (LCAT)
activity. The increased lipid transfer activities of
CETP and PLTP may explain the higher potential for
plasma to convert mature HDL into preb-HDL par-
ticles (Table 1). LCAT activity is essential for con-
verting unesterified cholesterol into cholesteryl
esters, and via this mechanism, LCAT induces the
transformation of preb-HDL into mature spherical
HDL. Reduced LCAT may thus contribute to the
higher contents of unesterified cholesterol and apoE
and the reduced content of apoA-I in mature FH
HDL (Table 1). We also determined macrophage
cholesterol efflux to apoB-depleted plasmas, which
contains mature HDL, the HDL regulatory proteins,
and preb-HDL particles, thereby permitting optimal
HDL remodeling and cholesterol flow to HDL. ApoB-
depleted plasma from patients with FH displayed an
impaired ability to promote macrophage cholesterol
efflux under experimental settings that stimulated
mainly ABCA1-dependent cholesterol efflux by
treating the cells with cyclic adenosine mono-
phosphate or that stimulated concerted action of
ABCA1/ABCG1-dependent efflux pathways by over-
loading the cells with acetylated-LDL (Table 1).
Notably, most of these HDL alterations were also
